Navigation Links
Stonegate Report About Unigene Laboratories Inc.
Date:3/13/2008

ral and administrative costs should show minimal increases for the last quarter of FY07 and throughout FY08.

Importantly, Unigene restructured its loan obligations earlier this year in May 2007 and eliminated its "going concern" status. The loans are primarily from officers and total approximately $16 million. They are now recast over eight years at 9 percent interest with no payments due (interest will accrue) for the first three years and no prepayment penalties.

With Fortical gaining market share, an advancing pipeline targeting large markets, a near-term positive bottom line, and huge upside potential, we believe that Unigene represents a significant opportunity for investors.

Risks

UGNE currently has only one product on the market. Any changes in market demand, USL's ability to market the product, any regulatory changes, or any delays in production would have a significant negative impact on the Company.

UGNE has products in its pipeline in various stages of development; however, Unigene may never develop another product that receives regulatory approval.

Unigene has incurred significant operating losses since its inception. The most recent quarter (September 2007) showed an accumulated deficit of $121.6 million. UGNE is dependent on partnerships and collaborations in the development of its pipeline. The Company's inability to establish new partnerships and to maintain current corporate partnerships and licensing arrangements would negatively impact the progress of the Company.

The pharmaceutical industry is extremely competitive in general, and with the aging population swelling the ranks of osteoporosis sufferers, competition in this market has heated up. Unigene competes with large companies with established products and other therapies that may emerge and displace calcitonin.

Indication: The complete report including tables and pictures can be downloaded free of charge as a pdf-file under

SOURCE Unigene Laboratories Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
2. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
3. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
4. Helix BioPharma reports Q2 2008 highlights, financial results
5. Oncothyreon reports full year and fourth quarter 2007 financial results
6. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
7. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
8. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 13
9. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
10. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
11. ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... March 03, 2015 Genedata, a ... discovery and life science research, today announced that ... enterprise platform for use at Pfizer biopharma research ... Genedata is supporting Pfizer’s global deployment and roll ... Centers for Therapeutic Innovation (CTI), and Pharmaceutical Sciences ...
(Date:3/3/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/gxqhg9/gene_therapy ) ... report "Gene Therapy - Technologies, Markets and ... Gene therapy technologies are described in detail ... with genetically modified vectors. Gene therapy is an ... of administration as well as targeted gene therapy ...
(Date:3/3/2015)... -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific ... protecting the microbiome, announced today that Jeffrey Riley , ... Annual ROTH Conference being held on March 8-11, 2015 at ... Dana Point, CA. Mr. Riley is scheduled ... (Pacific Time). A live webcast of Synthetic Biologics, ...
(Date:3/3/2015)... , March 2, 2015  Phillip Sharp, Institute Professor at ... of the Department of Biology and the Koch Institute for Integrative ... at Heritage Day , May 14, at the ... the Othmer Gold Medal since it was first awarded ... "In 1977 Phil Sharp gave the scientific world ...
Breaking Biology Technology:Genedata Biologics Licensed by Pfizer Inc. 2Genedata Biologics Licensed by Pfizer Inc. 3Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 2Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 3Synthetic Biologics to Present at the 27th Annual ROTH Conference 2Phillip Sharp to Receive 2015 Othmer Gold Medal 2Phillip Sharp to Receive 2015 Othmer Gold Medal 3
... President, Wyeth Research -, MADISON, N.J., April 30 ... R. Ruffolo, Jr., Ph.D., 58, will retire as,President, Wyeth ... will be succeeded by Mikael Dohlsten, M.D., Ph.D., ... been responsible for,all pharmaceutical research and development (R&D) for ...
... Today John C. Lechleiter,Ph.D., president and CEO of ... praised the,Bay State for its investment in biotechnology ... and a roadmap for ensuring the state,s significant,investment ... Massachusetts Biz/Bio,Conference, a gathering of policymakers, business leaders ...
... Another Top Flight Sport,s Training Institute joins ... April 30 Millennium,Biotechnologies Inc., wholly-owned subsidiary ... MBTG), announced today that SURGEX(TM) has,become the ... Training Facility, http://www.edgebasketball.com, Florida,s premier basketball ...
Cached Biology Technology:Wyeth Research Head Robert R. Ruffolo, Jr., Ph.D., Announces Retirement 2Lilly CEO Praises Massachusetts' Leadership in Biotech, Urges Policy Prescriptions to Help Ensure State's Investment Generates Dividends and Jobs 2Lilly CEO Praises Massachusetts' Leadership in Biotech, Urges Policy Prescriptions to Help Ensure State's Investment Generates Dividends and Jobs 3SURGEX(TM) Becomes the Official Sports Nutrition Drink of Former NBA Player Dee Brown and his Edge Basketball Training Facility 2SURGEX(TM) Becomes the Official Sports Nutrition Drink of Former NBA Player Dee Brown and his Edge Basketball Training Facility 3
(Date:1/22/2015)... 2015 Technology Showcase, Hall E -   EyeLock Inc. ... announced it will showcase its EyeLock ID technology integrated in ... of Energy,s Oak Ridge National Laboratory (ORNL) at ... iris identity authentication technology is being used to validate the ...
(Date:1/22/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) a ... the recent success of the Wocket™ smart wallet at CES 2015 in ... was named as one of the "11 Hot Products at CES" in ... At CES So Far" by Newseveryday.com and "The top 10 gadgets from ...
(Date:1/22/2015)... , Europe,s ... European Patent Office to present a video retrospective of the most ... featured: Christofer Toumazou and Sophie Wilson   ... of the Award   Starting on 22 January 2015 ...
Breaking Biology News(10 mins):EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3
... When Atlantic Richfield Co. was tasked with cleaning up a ... Hons, a Texas A&M University professor, got a call to ... soil and crop science professor, spent two years leading a ... 100 years of copper mining, mineral processing and smelting in ...
... have identified a new compound that could treat certain types ... step in what they hope will lead to human clinical ... dystrophy, or DMD, is a degenerative muscle disease that affects ... and cardiac muscles, severely limiting the life span of sufferers. ...
... is to bring experts and students together to discuss ... modeling. The objectives are to: Recognize the ... modeling codes, and tell the story lines of advancements ... establish the current state of the science/technology; and, Project ...
Cached Biology News:Mining cleanup benefits from Texas A&M expertise 2Mining cleanup benefits from Texas A&M expertise 3New compound holds promise for treating Duchenne MD, other inherited diseases 250 Years of Watershed Modeling -- Past, Present and Future 250 Years of Watershed Modeling -- Past, Present and Future 350 Years of Watershed Modeling -- Past, Present and Future 4
... Rabbit polyclonal to Neuron navigator 1 ( ... Antigen: Synthetic peptide conjugated to KLH ... of Mouse Neuron navigator 1. (Note: the ... (Peptide available as ab32208 .) ...
Mouse HAI-1 Ectodomain MAb (Clone 199732)...
pETDuet-1 is designed for the coexpression of two target genes....
Human IL-29/IFN-lambda 1 Biotinylated Affinity Purified PAb...
Biology Products: